title: Rat xenograft survival in mice treated with donor-specific transfusion and anti-CD154 antibody is enhanced by elimination of host CD4+ cells.
abstract: BACKGROUND
  Treatment with a donor-specific transfusion (DST) and a brief course of anti-mouse CD154 (anti-CD40-ligand) monoclonal antibody (mAb) prolongs the survival of both allografts and rat xenografts in mice. The mechanism by which allograft survival is prolonged is incompletely understood, but depends in part on the presence of CD4+ cells and the deletion of alloreactive CD8+ T cells. Less is known about the mechanism by which this protocol prolongs xenograft survival.
  
  
  METHODS
  We measured rat islet and skin xenograft survival in euthymic and thymectomized mice treated with combinations of DST, anti-CD154 mAb, anti-CD4 mAb, and anti-CD8 mAb. Recipients included C57BL/6, C57BL/6-scid, C57BL/6-CD4null, and C57BL/6-CD8null mice.
  
  
  RESULTS
  Pretreatment with a depleting anti-CD4 mAb markedly prolonged the survival of both skin and islet xenografts in mice given DST plus anti-CD154 mAb. Comparable prolongation of xenograft survival was obtained in C57BL/6-CD4null recipients treated with DST and anti-CD154 mAb. In contrast, anti-CD8 mAb did not prolong the survival of either islet or skin xenografts in mice treated with DST and anti-CD154 mAb. Thymectomy did not influence xenograft survival in any treatment group. Adoptive transfer of splenocytes from C57BL/6-CD4null recipients treated with DST and anti-CD154 mAb and bearing long-term skin xenografts revealed the presence of residual xenoreactive cells.
  
  
  CONCLUSIONS
  These data suggest that treatment with DST and anti-CD154 mAb induces a state of "functional" transplantation tolerance. They also support the hypothesis that both the induction and maintenance of graft survival based on this protocol depend on different cellular mechanisms in allogeneic and xenogeneic model systems.
authors.affiliation: Diabetes Division, University of Massachusetts Medical School, Worcester 01605, USA.
authors.forename: E J
authors.initials: EJ
authors.lastname: Gordon
authors.forename: B A
authors.initials: BA
authors.lastname: Woda
authors.forename: L D
authors.initials: LD
authors.lastname: Shultz
authors.forename: A A
authors.initials: AA
authors.lastname: Rossini
authors.forename: D L
authors.initials: DL
authors.lastname: Greiner
authors.forename: J P
authors.initials: JP
authors.lastname: Mordes
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D001803:Blood Transfusion; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology*; D023201:CD40 Ligand / Q000276:immunology*; D006085:Graft Survival / Q000276:immunology / Q000502:physiology*; D008212:Lymphocyte Depletion; D051379:Mice; D008810:Mice, Inbred C57BL; D051381:Rats; D011917:Rats, Inbred Lew; D014183:Transplantation, Heterologous / Q000276:immunology*
chemical_list: D000906:Antibodies; D023201:CD40 Ligand